+AA
Fr

Treating behavioural problems of dementia: When confusion leads to controversy

The Bottom Line

  • Behavioural problems associated with dementia are a common serious source of suffering for both patient and caregiver. These behavioural problems require specific treatment.
  • Treatment should always include appropriate assessment and diagnosis. This should be followed by non-drug treatments, such as environmental or behavioural interventions.
  • If medications are required, be sure to understand the potential benefits and the possible risks. Caregivers will need to ensure the patient will be monitored for side effects.

What is the problem?

Approximately 8% of people over 65 in Canada suffer from dementia. While two-thirds of dementia is caused by Alzheimer's disease, there are many other causes including dementia associated with other medical conditions like stroke and Parkinson's disease. Dementia is characterized by cognitive impairment (problems with memory, language, concentration, etc.), difficulties with activities of daily living (cooking, cleaning, finances, dressing, grooming, etc.) and behaviour problems. Up to 90% of people with Alzheimer's disease will develop behaviour problems over the course of their illness including depression, anxiety, agitation, aggression, psychosis (hallucinations and delusions) and apathy (loss of interest, lack of motivation). It is these behaviours, also known as the "neuropsychiatric symptoms of dementia", that cause suffering for the patient, increase burden and caregiver stress, and increase the cost of care. Behaviours such as agitation and aggression lead to caregiver burnout and the premature need for institutionalization. Treating these neuropsychiatric symptoms is important in order to relieve the patients' suffering, reduce caregiver burden, and hopefully delay the need for long-term care.


What is the treatment?

The Canadian Consensus Conference on the Diagnosis and Treatment of Dementia has met four times over the last two decades to provide Canadian physicians with guidelines for managing dementia based on the best available medical evidence. The guidelines stress that treatment of behavior problems begins with careful assessment and diagnosis (1). There should be some consideration of other causes of changes in behaviour, which could include:

  1. a new medical illness (e.g. urinary tract infection),
  2. pain,
  3. sensory impairment (uncorrected hearing or vision),
  4. reactions to changes in the environment (e.g. moving, changes of caregivers), and
  5. medication side effects.


If changes to these factors do not improve behaviour, then environmental and behavioural interventions should be instituted. There is increasingly good evidence that these non-medication treatments are effective and safe(2) , though different behaviours require different interventions. For example, music can be particularly beneficial for symptoms of anxiety and depression and may be helpful for agitation and aggression (3). Teaching caregivers behavioural interventions can improve a variety of problems including agitation, aggression and apathy (4). These behavioural interventions can include:

  1. addressing unmet needs,
  2. reinforcing positive behaviours,
  3. ignoring negative behaviours.


Providing supportive counselling for caregivers can improve both patient and caregiver depressive symptoms (5).

If non-medication interventions are not effective enough, then physicians could consider drugs for some of these behavior problems. Drug treatment could include the typical Alzheimer's disease drugs like donepezil, galantamine, rivastigmine and memantine. These drugs appear to have modest benefits for treating apathy, depression, agitation and psychosis (6). Specific psychiatric medications, such as antidepressants, antipsychotics and antianxiety drugs, have been used to treat behavior problems as well (7).



So what is the controversy?

The psychiatric medications mentioned previously are being used far too frequently in patients with dementia. This is often before appropriate assessment, diagnosis and non-medication treatments have been given to them. In Ontario, anywhere from one-third to two-thirds of nursing home residents with dementia are being treated with antipsychotics. These drugs have modest effects on agitation, aggression and psychosis. They also have well-known serious side effects including excessive sedation, Parkinson's disease-type symptoms, increased risk of stroke and even a small increased risk of death. Canadian treatment guidelines (8) clearly state that these drugs should only be used for severe agitation, aggression and psychosis; use should also be considered only when there is risk of harm to the patient or others in their environment. Furthermore, the benefits must be weighed against the significant risks mentioned above. The caregiver who provides substitute consent must be informed of these potential adverse effects.


Get the latest content first. Sign up for free weekly email alerts.
Subscribe
Author Details

References

  1. Herrmann N, Gauthier S. Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease. CMAJ 2008 Dec 2;179(12):1279-87.
  2. O'Neil ME, Freeman M, Christensen V, Telerant R, Addleman A, Kansagara D. Non-pharmacological Interventions for Behavioral Symptoms of Dementia: A Systematic Review of the Evidence. Department of Veterans Affairs; 2011 Mar. 
  3. Ueda T, Suzukamo Y, Sato M, Izumi S. Effects of music therapy on behavioral and psychological symptoms of dementia: a systematic review and meta-analysis. Ageing Res Rev 2013 Mar;12(2):628-41.
  4. Cohen-Mansfield J, Libin A, Marx MS. Nonpharmacological treatment of agitation: a controlled trial of systematic individualized intervention. J Gerontol A Biol Sci Med Sci 2007 Aug;62(8):908-16.
  5. Mittelman MS, Roth DL, Coon DW, Haley WE. Sustained benefit of supportive intervention for depressive symptoms in caregivers of patients with Alzheimer's disease. Am J Psychiatry 2004 May;161(5):850-6.
  6. Rodda J, Morgan S, Walker Z. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatr 2009 Oct;21(5):813-24.
  7. Herrmann N, Lanctot KL, Rothenburg LS, Eryavec G. A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dement Geriatr Cogn Disord 2007;23(2):116-9.
  8. Herrmann N, Lanctot KL, Hogan DB. Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimers Res Ther 2013 Jul 8;5(Suppl 1):S5.

DISCLAIMER: The blogs are provided for informational purposes only. They are not a substitute for advice from your own healthcare professionals.

Want the latest in aging research? Sign up for our email alerts.
Subscribe
© 2012 - 2019 McMaster University | 1280 Main Street West | Hamilton, Ontario L8S4L8 | +1 905-525-9140 | Terms Of Use